RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (MRK), known as MSD outside the United States and Canada, today announced positive results from the Phase 3 HYPERION trial evaluating WINREVAIR™ (sotatercept-csrk ...

WINREVAIR significantly reduced the risk of major morbidity and mortality events, the primary endpoint, in adults with PAH (Group 1 PH) WHO* functional class (FC) III or IV at high risk of mortality ...

Merck & Co. Inc. (NYSE:MRK) announced results Tuesday from its Phase 3 HYPERION trial evaluating Winrevair (sotatercept-csrk) versus placebo (both in combination with background therapy) in recently ...

Positive results from a proof-of-concept study evaluating Merck’s Winrevair pave the way for further study of the activin signaling inhibitor as a potential treatment for a subset of heart failure ...

The interim results of a phase 3 trial of Merck’s pulmonary arterial hypertension (PAH) treatment Winrevair were so conclusive that the company not only halted the study for efficacy, but did the same ...

Merck MRK announced that the phase III HYPERION study evaluating its pulmonary arterial hypertension (“PAH”) drug, Winrevair (sotatercept), in newly diagnosed intermediate or high-risk PAH patients, ...

Please provide your email address to receive an email when new articles are posted on . Fewer adults diagnosed with PAH less than 1 year ago receiving add-on Winrevair vs. placebo had at least one ...

Please provide your email address to receive an email when new articles are posted on . This decision was based on phase 3 ZENITH trial data assessing Winrevair in adults with WHO functional class III ...

Merck & Co. Inc. (NYSE: MRK) on Tuesday released topline results from the Phase 2 CADENCE study of Winrevair (sotatercept-csrk) in adults for combined post- and precapillary pulmonary hypertension ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review for a new ...

Merck, known as MSD outside of the United States and Canada, today announced the first presentation of results from the Phase 3 ZENITH trial evaluating WINREVAIR ™ (sotatercept-csrk) compared to ...